Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Panitumumab maintenance in colorectal cancer
NCT02337946Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2014
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in colorectal carcinoma (CRC) (2 arms), sponsored by Takeda. Primary endpoint: Progression-Free Survival Rate at 9 Months After Randomization. Started Oct 2014; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT02337946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337946.